Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Andreas HeerwigKurt-Schwabe-Institut für Mess- und Sensortechnik Meinsberg e.V., 04736 Waldheim, Germany.
Alfred KickKurt-Schwabe-Institut für Mess- und Sensortechnik Meinsberg e.V., 04736 Waldheim, Germany.
Paul SommerfeldInstitutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-8182-0347
Sophia EimermacherInstitutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-2311-3644
Frederick HartungInstitutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany.
Markus LaubeHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.ORCID 0000-0003-4916-3794
Dietmar FischerInstitutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-1816-3014
Hans-Jürgen PietzschHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.
Jens PietzschHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.ORCID 0000-0002-1610-1493
Reik LöserHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.ORCID 0000-0003-1531-7601
Michael MertigKurt-Schwabe-Institut für Mess- und Sensortechnik Meinsberg e.V., 04736 Waldheim, Germany.ORCID 0000-0002-8359-0135
Markus PietschInstitutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-8110-2265
Robert WodtkeHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.ORCID 0000-0001-7462-7111
Funding
Deutsche Forschungsgemeinschaft RTG 2767Europäischer Fonds für regionale Entwicklung 100367266Sächsische Aufbaubank 100357470
6 · The paper itself
Abstract
In addition to the classic functions of proteins, such as acting as a biocatalyst or binding partner, the conformational states of proteins and their remodeling upon stimulation need to be considered. A prominent example of a protein that undergoes comprehensive conformational remodeling is transglutaminase 2 (TGase 2), the distinct conformational states of which are closely related to particular functions. Its involvement in various pathophysiological processes, including fibrosis and cancer, motivates the development of theranostic agents, particularly based on inhibitors that are directed toward the transamidase activity. In this context, the ability of such inhibitors to control the conformational dynamics of TGase 2 emerges as an important parameter, and methods to assess this property are in great demand. Herein, we describe the application of the switchSENSE
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.